Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.
Read original article on The Medical News →Related news
-
New animal model offers more precise way to study calorie-burning brown fat
United Kingdom
-
53 Orangutans Rescued from Fires in Borneo, With Many Rewilded to Forest Preserves Across the Island
United Kingdom
-
Can psychedelics soothe an overactive immune system? New meta-analysis investigates
United Kingdom
-
Flood Worries? Tape Can Block 99% of Water Compared to Expensive Sandbags That Break Your Back
United Kingdom
-
Postpartum recovery window may play a critical role in maternal aging and long-term health
United Kingdom
-
A Chance Meeting in a Chinese Restaurant Saved a Man’s Life – As Everything Happens for a Reason
United Kingdom
-
Scientists reveal the hidden danger of missing blood pressure medication
United States
-
The Invisible Layer: Electromagnetic Exposure and Human Health in the Built Environment
United States